Država: Kanada
Jezik: angleščina
Source: Health Canada
LOVASTATIN
MYLAN PHARMACEUTICALS ULC
C10AA02
LOVASTATIN
40MG
TABLET
LOVASTATIN 40MG
ORAL
100
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0120669001; AHFS:
CANCELLED POST MARKET
2017-08-02
_ _ _Product Monograph –Mylan_-_Lovastatin Page 1 of 45_ PRODUCT MONOGRAPH PR MYLAN-LOVASTATIN Lovastatin Tablets, USP 20 mg and 40 mg LIPID METABOLISM REGULATOR Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Submission Control No.: 172776 Date of Revision: March 26, 2014 _ _ _Product Monograph –Mylan_-_Lovastatin Page 2 of 45 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 5 ADVERSE REACTIONS ................................................................................................. 13 DRUG INTERACTIONS ................................................................................................. 15 DOSAGE AND ADMINISTRATION ............................................................................. 18 OVERDOSAGE ............................................................................................................... 20 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 20 STORAGE AND STABILITY ......................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 21 PART II: SCIENTIFIC INFORMATION ............................................................................... 22 PHARMACEUTICAL INFORMATION ......................................................................... 22 CLINICAL TRIALS ......................................................................................................... 23 DETAILED PHARMACOLOGY .... Preberite celoten dokument